BioInvent International AB BOVNF:OTCPK

RT Quote | Exchange | USD
Last | 01/27/22 EDT
2.98UNCH (UNCH)
52 week range
2.98 - 6.63
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.98
  • 52 Week High6.63
  • 52 Week High Date12/23/21
  • 52 Week Low2.98
  • 52 Week Low Date01/27/22

Key Stats

  • Market Cap252.83M
  • Shares Out58.47M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.98
  • 52 Week High6.63
  • 52 Week High Date12/23/21
  • 52 Week Low2.98
  • 52 Week Low Date01/27/22
  • Market Cap252.83M
  • Shares Out58.47M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-0.48
  • P/E (TTM)-6.14
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On BioInvent International AB

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged...
Leonard Kruimer CPA
Independent Chairman of the Board
Martin Welschof Ph.D.
Chief Executive Officer
Marie Moores
Chief Operating Officer
Stefan Ericsson
Chief Financial Officer
Address
Ideon Science Park
Lund
223 70
Sweden